KRAS and neoplasm: In 2019, it had already been reported that the loss of Atrx enhanced pancreatic injury and susceptibility to KRAS-mediated (M.K.Atrx) pancreatic damage in female mice, pioneering the attribution of anti-inflammatory and tumour-suppressive roles to Atrx [36] (Table 1).